Flowonix Medical Inc.
At Flowonix, our patient centric approach drives the design, development, and deployment of targeted drug delivery platforms whose sole purpose is to provide physicians an optimal solution for the treatment of their patients` numerous neurological disorders.
Company details
Find locations served, office locations
- Business Type:
- Manufacturer
- Industry Type:
- Medical Equipment
- Market Focus:
- Nationally (across the country)
- Employees:
- 101-1000
Core Values
- Character – The common thread of our culture. One is never wrong doing what is right.
- Integrity – Saying exactly what we mean and doing what we say.
- Relentless – While never at the expense of progress, we push for perfection.
- Purpose – Optimizing patient outcomes is our greater cause.
Advancements
The engineering team at Flowonix has a rich history of developing the technology to efficiently deliver medication when a patient needs it most.
Our team continues to innovate and is proud to hold 12 issued patents and an additional 7 patents pending. A leader in the industry, our team has been responsible for many early drug delivery systems, including:
- First implant for anticoagulant Heparin
- First human implant for Floxuridine (FUDR, an anti-cancer chemotherapy drug)
- First human implant for insulin
- First human implant for morphine
- First valve regulated intrathecal pump
- US Patents on:
- Programmable valve pumps
- Implantable, refillable pumps
- Long life power supplies for implantable pumps
- Septumless implantable pumps
- Low power electromagnetic valves
- Pump diagnostic systems
Compliance Program
At Flowonix Medical, we take our responsibility to the community very seriously and consistently work to achieve the highest standards of corporate conduct.
Our commitment as a healthcare company is to create innovative solutions of the highest quality for unmet medical needs, thereby enhancing the health and quality of life for those with chronic conditions. We are dedicated to meeting our mission in a responsible and ethical manner and with a commitment to sustainable development, respecting the needs of the individual, the society, and the environment.
As a part of this effort, we have adopted a compliance program that addresses the matters covered by the Federal Register May 2003 publication 'Compliance Program Guidance for Pharmaceutical Manufacturers' ('OIG Guidance'), which was developed by the United States Department of Health and Human Services Office of Inspector General ('HHS-OIG') and is also applicable to medical device manufacturers.